RU2014145121A - Пиримидиновые соединения для лечения злокачественной опухоли - Google Patents
Пиримидиновые соединения для лечения злокачественной опухоли Download PDFInfo
- Publication number
- RU2014145121A RU2014145121A RU2014145121A RU2014145121A RU2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- connection
- compound
- cycloalkyl
- malignant tumor
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 7
- 125000003118 aryl group Chemical group 0.000 claims abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 125000005936 piperidyl group Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract 2
- 125000005842 heteroatom Chemical group 0.000 claims abstract 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims abstract 2
- 125000005647 linker group Chemical group 0.000 claims abstract 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical group O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650000P | 2012-05-22 | 2012-05-22 | |
| US61/650,000 | 2012-05-22 | ||
| PCT/US2013/042033 WO2013177168A1 (en) | 2012-05-22 | 2013-05-21 | Pyrimidine compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014145121A true RU2014145121A (ru) | 2016-07-10 |
Family
ID=49624289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014145121A RU2014145121A (ru) | 2012-05-22 | 2013-05-21 | Пиримидиновые соединения для лечения злокачественной опухоли |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9567326B2 (OSRAM) |
| EP (1) | EP2852579A4 (OSRAM) |
| JP (1) | JP2015517574A (OSRAM) |
| KR (1) | KR20150018789A (OSRAM) |
| CN (1) | CN104302627A (OSRAM) |
| AU (1) | AU2013266438B2 (OSRAM) |
| BR (1) | BR112014028424A2 (OSRAM) |
| CA (1) | CA2873878A1 (OSRAM) |
| HK (1) | HK1206338A1 (OSRAM) |
| IL (1) | IL235726A0 (OSRAM) |
| IN (1) | IN2014DN09610A (OSRAM) |
| MX (1) | MX2014013632A (OSRAM) |
| RU (1) | RU2014145121A (OSRAM) |
| WO (1) | WO2013177168A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| CN103958510B (zh) | 2011-10-03 | 2016-10-19 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的吡咯并嘧啶化合物 |
| CN104302627A (zh) | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的嘧啶化合物 |
| WO2014058685A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| US9771330B2 (en) | 2012-11-27 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| CN104926801B (zh) * | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
| US20150291606A1 (en) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
| US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2018005356A1 (en) | 2016-06-27 | 2018-01-04 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
| CN106749173A (zh) * | 2016-11-25 | 2017-05-31 | 吉林化工学院 | 一种嘧啶联吡啶类化合物的制备方法 |
| US11053225B2 (en) | 2017-05-02 | 2021-07-06 | Korea Research Institute Of Chemical Technology | Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3 related disease comprising same as active ingredient |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP3498694A1 (en) * | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2022059996A1 (ko) * | 2020-09-15 | 2022-03-24 | 서울대학교 기술지주 주식회사 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
| KR102616469B1 (ko) * | 2020-09-15 | 2023-12-28 | 주식회사 유엔에스바이오 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
| MX2023006434A (es) * | 2020-12-16 | 2023-06-13 | Abm Therapeutics Corp | Inhibidores de quinasa y usos de los mismos. |
| CN119059982B (zh) * | 2024-07-18 | 2025-09-19 | 河北科技大学 | 一种异羟肟酸类Mer/HDAC双靶点抑制剂及其制备方法和应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH549339A (de) * | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
| US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| CN1657523A (zh) * | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| AU2002341920A1 (en) | 2001-10-02 | 2003-04-14 | Smithkline Beecham Corporation | Chemical compounds |
| ES2373226T3 (es) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| WO2004106339A2 (en) | 2003-05-28 | 2004-12-09 | Università Degli Studi Di Siena | 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7138401B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
| JP5520433B2 (ja) | 2004-01-21 | 2014-06-11 | エモリー ユニバーシティー | 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用 |
| JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| DK1713806T3 (da) | 2004-02-14 | 2013-08-05 | Irm Llc | Forbindelser og sammensætninger som proteinkinaseinhibitorer |
| WO2005095382A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
| US7897607B2 (en) | 2004-04-07 | 2011-03-01 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| BRPI0516746A (pt) * | 2004-09-30 | 2008-09-23 | Tibotec Pharm Ltd | 5-heterociclil pirimidinas para inibição de hiv |
| WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| EP1937258A2 (en) | 2005-09-23 | 2008-07-02 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CN101321751A (zh) * | 2005-09-30 | 2008-12-10 | 布里斯托尔-迈尔斯·斯奎布公司 | Met激酶抑制剂 |
| WO2007044426A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| CN101360761B (zh) | 2005-12-08 | 2012-09-12 | 米德列斯公司 | 抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途 |
| US20080299113A1 (en) | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
| EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
| ES2465666T3 (es) * | 2006-03-30 | 2014-06-06 | Janssen R&D Ireland | Pirimidinas 5-amido-sustituidas inhibidoras del HIV |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| WO2008111441A1 (ja) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | 医薬組成物 |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| AU2008309517B2 (en) | 2007-10-12 | 2013-03-14 | Astrazeneca Ab | Inhibitors of protein kinases |
| CA2960659C (en) | 2007-11-09 | 2021-07-13 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8450335B2 (en) * | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| WO2010014755A1 (en) | 2008-07-29 | 2010-02-04 | The Regents Of The University Of Colorado | Methods and compounds for enhancing anti-cancer therapy |
| US8569466B2 (en) | 2008-09-10 | 2013-10-29 | Nnochiri Ekwuribe | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers |
| WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| WO2010117425A1 (en) | 2009-03-31 | 2010-10-14 | Biogen Idec Ma Inc. | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
| AU2010294209A1 (en) | 2009-09-10 | 2012-03-29 | Irm Llc | Ether derivatives of bicyclic heteroaryls |
| WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| EP2536410B1 (en) | 2010-02-18 | 2015-09-23 | Merck Sharp & Dohme Corp. | Substituted pyrimidine derivatives and their use in treating viral infections |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| WO2012066578A2 (en) | 2010-11-18 | 2012-05-24 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| AR091790A1 (es) * | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| PH12014500638A1 (en) | 2011-09-22 | 2017-08-09 | Pfizer | Pyrrolopyrimidine and purine derivatives |
| CN103958510B (zh) | 2011-10-03 | 2016-10-19 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的吡咯并嘧啶化合物 |
| JP2015509943A (ja) | 2012-02-21 | 2015-04-02 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ウイルス侵入補助因子としてのｔａｍレセプター |
| HUE036582T2 (hu) * | 2012-04-17 | 2018-07-30 | Fujifilm Corp | Nitrogéntartalmú heterociklusos vegyület vagy annak sója |
| AU2013250726B2 (en) | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| CN104302627A (zh) | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的嘧啶化合物 |
| WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| US9771330B2 (en) | 2012-11-27 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| US20170202847A1 (en) | 2014-04-04 | 2017-07-20 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
| US20150291606A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
-
2013
- 2013-05-21 CN CN201380025291.3A patent/CN104302627A/zh active Pending
- 2013-05-21 RU RU2014145121A patent/RU2014145121A/ru not_active Application Discontinuation
- 2013-05-21 JP JP2015514115A patent/JP2015517574A/ja active Pending
- 2013-05-21 HK HK15106878.7A patent/HK1206338A1/xx unknown
- 2013-05-21 KR KR1020147032028A patent/KR20150018789A/ko not_active Withdrawn
- 2013-05-21 US US14/384,789 patent/US9567326B2/en active Active
- 2013-05-21 WO PCT/US2013/042033 patent/WO2013177168A1/en not_active Ceased
- 2013-05-21 AU AU2013266438A patent/AU2013266438B2/en not_active Expired - Fee Related
- 2013-05-21 EP EP13793925.2A patent/EP2852579A4/en not_active Withdrawn
- 2013-05-21 IN IN9610DEN2014 patent/IN2014DN09610A/en unknown
- 2013-05-21 BR BR112014028424A patent/BR112014028424A2/pt not_active Application Discontinuation
- 2013-05-21 CA CA2873878A patent/CA2873878A1/en not_active Abandoned
- 2013-05-21 MX MX2014013632A patent/MX2014013632A/es unknown
-
2014
- 2014-11-16 IL IL235726A patent/IL235726A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2873878A1 (en) | 2013-11-28 |
| IL235726A0 (en) | 2015-02-01 |
| HK1206338A1 (en) | 2016-01-08 |
| IN2014DN09610A (OSRAM) | 2015-07-31 |
| AU2013266438B2 (en) | 2017-09-07 |
| CN104302627A (zh) | 2015-01-21 |
| US9567326B2 (en) | 2017-02-14 |
| KR20150018789A (ko) | 2015-02-24 |
| US20150038481A1 (en) | 2015-02-05 |
| EP2852579A1 (en) | 2015-04-01 |
| JP2015517574A (ja) | 2015-06-22 |
| MX2014013632A (es) | 2015-02-05 |
| BR112014028424A2 (pt) | 2018-04-24 |
| EP2852579A4 (en) | 2015-12-30 |
| WO2013177168A1 (en) | 2013-11-28 |
| AU2013266438A1 (en) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014145121A (ru) | Пиримидиновые соединения для лечения злокачественной опухоли | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2015517574A5 (OSRAM) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2013112871A (ru) | Соединения для лечения рака | |
| RU2016125705A (ru) | Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов | |
| RU2012110246A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| JP2016503799A5 (OSRAM) | ||
| RU2015101106A (ru) | Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| RU2013155586A (ru) | [1,3]оксазины | |
| JP2012515776A5 (OSRAM) | ||
| MX2010009959A (es) | Compuestos y metodo para reducir el acido urico. | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| JP2017508782A5 (OSRAM) | ||
| RU2012144022A (ru) | МОДУЛЯТОРЫ АКТИВНОСТИ Нес1 И СПОСОБЫ ДЛЯ НИХ | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2013538213A5 (OSRAM) | ||
| JP2015512943A5 (OSRAM) | ||
| RU2015150120A (ru) | Соединение дикарбоновой кислоты | |
| RU2013134480A (ru) | Таргетирование раковых опухолей за счет использования ингибиторов изоформ карбоангидразы ix | |
| RU2009144538A (ru) | Новые циклические пептидные соединения | |
| RU2014101953A (ru) | Агонисты протеинтирозинфосфатазы-1, содержащие домен гомологии-2 src, и способы лечения с применением указанных агонистов | |
| RU2016147654A (ru) | Соединения для лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171020 |